Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 15;22(3):175–183. doi: 10.1080/15384047.2020.1834792

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Taylor & Francis Group, LLC

PMC Copyright notice

Figure 4. — Summary of imaging scans and timeline of therapy and disease status for Case 4

(a) Baseline status before treatment with Nivolumab and radiotherapy (RT). (b) MRI images 20 days after radiotherapy revealed decreased size of the radiation-targeted lesion. (c, d, and e) Evidence of complete remission after treatment with Everolimus combined with Pembrolizumab. The patient then underwent radical surgical resection. (f) MRI scans obtained 3 months after surgical resection showed that the tumor was complete resected. (g) Serum carbohydrate antigen 199 (CA199) and alpha-fetoprotein (AFP) levels with respect to the treatment timeline. (h) Statistics of maximum diameter of the lesion. Seven months after Nivolumab treatment, the patient achieved partial response (RECIST criteria). (i) Timeline showing therapy and disease status throughout the disease course.